{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:03:36Z","timestamp":1759190616121,"version":"3.44.0"},"reference-count":4,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2025.1697374","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:26:11Z","timestamp":1759123571000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Exploring the impact of biologics in nephrology: clinical advances and future perspectives"],"prefix":"10.3389","volume":"12","author":[{"given":"Marta","family":"Calatroni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel A.","family":"Podest\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cucchiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Reggiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/ndt\/gfae025","article-title":"Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group","volume":"39","author":"Mirioglu","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf156","article-title":"Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: biological challenges and clinical implications","author":"Raglianti","year":"2025","journal-title":"Nephrol Dial Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/ndt\/gfae012","article-title":"Initial rituximab monotherapy for adult indiopathic nephrotic syndrome with minimal change lesion pattern","volume":"39","author":"Xu","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1403562","DOI":"10.3389\/fphar.2024.1403562","article-title":"The efficacy and safety of half-dose glucocorticoids combined with rituximab versus high-dose glucocorticoids for initial treatment of minimal change disease: a single-center experience","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1697374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:26:11Z","timestamp":1759123571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1697374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":4,"alternative-id":["10.3389\/fmed.2025.1697374"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1697374","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1697374"}}